Sharemaestro Newsreel

Ovid Therapeutics earnings beat by $0.04, revenue topped estimates

TENX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Tenax Therapeutics

SueWallSt is investigating potential securities claims against Tenax Therapeutics (TENX) after its shares dropped 84-85% following the failure of its Phase 3 LEVEL trial of TNX-103 to meet primary and key secondary endpoints. Investors who suffered losses due to this decline are encouraged to …

Janus Henderson Group (IMMX) discloses 9.78M-share beneficial stake in Immix Biopharma

Janus Henderson Group Ltd., through its investment adviser subsidiaries, has reported a beneficial ownership of 9,783,192 shares of Immix Biopharma, Inc. common stock, representing 14.0% of the class. These shares are held in client accounts, known as Managed Portfolios, where Janus Henderson's asset managers …

Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock. By their very nature, these stocks carry above-average risk and volatility. …

Celcuity LLC (CELC) enters earnings with mixed weekly signals

A near-term rebound contrasts with deeper medium-term losses before the oncology biotech reports.

Janus Henderson Group (JANX) reports 172,229 Janux Therapeutics shares under management

Janus Henderson Group Ltd. has reported beneficial ownership of 172,229 shares of Janux Therapeutics, Inc. common stock, which represents a 0.3% stake in the company. These shares are held across various client accounts managed by Janus Henderson's investment adviser subsidiaries, and the group exercises …

Eupraxia Pharmaceuticals (EPRX) holders report around 4–5% stakes in 13G/A

An amended Schedule 13G filing for Eupraxia Pharmaceuticals (EPRX) reveals that Manchester Management Company, LLC, Manchester Management PR, LLC, Manchester Explorer, L.P., James E. Besser, and Morgan C. Frank each report beneficial ownership of common shares ranging from approximately 4.1% to 4.5% of the …

Gossamer Bio Inc (GOSS) News, Articles, Events & Latest Updates

Gossamer Bio Inc (GOSS) recently reported its Q2 2026 financial results, showing a loss but exceeding revenue estimates. The company, a clinical-stage biopharmaceutical firm, is focusing on developing seralutinib for pulmonary arterial hypertension. Several legal firms are investigating the company, and its stock has …

Revolution Medicines (RVMD): Janus Henderson discloses 5.1% beneficial stake

Janus Henderson Group Ltd. has disclosed a 5.1% beneficial ownership stake in Revolution Medicines, Inc. (RVMD), holding 10,736,145 shares of common stock. These shares are managed across various client portfolios, with Janus Henderson exercising shared voting and dispositive power but disclaiming economic ownership, which …

Janus Henderson Group Ltd. (TARS) discloses 6.5% beneficial stake in Tarsus

Janus Henderson Group Ltd. has disclosed a 6.5% beneficial ownership stake in Tarsus Pharmaceuticals, Inc., totaling 2,808,796 shares of common stock. This ownership is held through its affiliated asset managers via Managed Portfolios, where they exercise investment and voting discretion. The filing indicates shared …

GeoVax Labs (GOVX) holders report 1.59% stake tied to 118,715 warrants

Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and Waqas Khatri collectively reported beneficial ownership of 118,715 shares of GeoVax Labs (GOVX) common stock through warrants. This represents a 1.59% stake based on 7,369,243 shares outstanding as of July …

Janus Henderson Group (ACHV) reports 5,502,064 Achieve Life shares under management

Janus Henderson Group Ltd., through its affiliated asset managers, has disclosed beneficial ownership of 5,502,064 shares of Achieve Life Sciences, Inc. (ACHV) common stock, representing 5.4% of the outstanding shares. These shares include those obtainable via warrants and are held in various Managed Portfolios, …

ADC Therapeutics SA: Shareholders Board Members Managers and Company Profile | CH0499880968

This page provides a detailed company profile for ADC Therapeutics SA, a Switzerland-based clinical-stage oncology drug discovery and development company. It outlines the company's business description, sales by activity and geographical breakdown, executive committee, board of directors, and major shareholders. Financial data, analyst consensus, …

Lenz drops as BofA downgrades on a slower VIZZ launch

[Republican Politics and Wall Street] Douglas Rissing Shares of Lenz Therapeutics (LENZ [https://seekingalpha.com/symbol/LENZ]) slipped for the third consecutive session on Thursday after Bank of America downgraded the eye drug developer to Neutral from Buy, citing a slower-than-expected rollout of its presbyopia therapy VIZZ. In …

Why is MeiraGTx stock surging today?

MeiraGTx Holdings PLC stock surged 6.3% following a dramatic beat on Q2 2026 earnings, reporting $1.71 EPS against an expected loss and revenue of $321.4 million. The company's financial turnaround was supported by strategic deals, FDA Breakthrough Therapy Designation, and a significantly strengthened balance …

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL

SueWallSt is reminding shareholders of Replimune Group, Inc. (REPL) about a lead plaintiff deadline of October 5, 2026, in a securities class action lawsuit. The lawsuit alleges that Replimune made misleading statements regarding the FDA's review of its RP1 resubmission, leading to an 84% …

Lenz stock drops as Bank of America downgrades (LENZ:NASDAQ)

Lenz Therapeutics' stock fell for the third straight day after Bank of America downgraded the company from Buy to Neutral. The downgrade was attributed to a slower-than-expected launch of its presbyopia therapy, VIZZ. Analyst Jason Gerberry also lowered his price target for LENZ.

ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus

Altimmune (ALT) reported a narrower-than-expected loss of 12 cents per share in Q2 2026, beating the Zacks Consensus Estimate of 15 cents. The company, which currently has no marketed drugs, focused on advancing its lead candidate, pemvidutide, with ongoing clinical studies for MASH, AUD, …

Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors

Vertex Pharmaceuticals Inc. (VRTX) saw its stock decline by 1.77% on Thursday, closing at $516.44. This underperformance occurred despite a generally favorable trading day for the broader market, with both the S&P 500 and Dow Jones Industrial Average posting gains. This marks the second …

Nuvation Bio (NUVB) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8 a.m. ET CALL PARTICIPANTS Vice President of Corporate Development and Investor Relations - Robert DeVitaFounder, President and Chief Executive Officer - David HungChief Commercial Officer - Colleen SjogrenChief Financial Officer - Philippe …

Praxis (PRAX) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Marcio De'SouzaChief Financial Officer - Tim KellyPresident of Research and Development - Steve PetrouChief Operating Officer - Megan Sniecinski TAKEAWAYS Cash and …

Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates

Genelux Corporation announced its second-quarter 2026 financial results and provided business updates, including anticipated topline data from its Phase 3 OnPrime/GOG-3076 ovarian cancer trial in the second half of 2026. The company reported $18.7 million in cash, cash equivalents, marketable securities, and restricted cash …

Caris Life Sciences, Inc. - Common Stock (CAI) Stock Price, News, Quote & History

Valion Bio (Nasdaq:VBIO) - analisi del titolo

This article provides an analysis of Valion Bio (Nasdaq: VBIO), an advanced-stage biopharmaceutical company with a market capitalization of US$546.7k. The company is developing Entolimod for Acute Radiation Syndrome (ARS) and oncology supportive care, facing significant risks including a highly volatile stock price, declining …

AQR group (VRXA) discloses 658,138-share Veraxa Biotech position under 5% threshold

AQR Capital Management, along with its affiliates, has reported a beneficial ownership of 658,138 Ordinary Shares in Veraxa Biotech Holding AG, which includes warrants. This position represents 0.46% of Veraxa’s outstanding Ordinary Shares, confirming that the AQR group holds less than the 5% threshold. …

Replimune Group Stock Short Interest Rises to 57.95%

Replimune Group Inc. (NASDAQ:REPL) saw a significant increase in short interest during July, rising 57.95% to 5.25 million shares. This represents 14.7% of the company's shares outstanding, indicating a growing bearish sentiment among investors. The average daily trading volume suggests it would take approximately …

Stifel Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $318

Stifel has reiterated its Buy rating on Alnylam Pharmaceuticals (ALNY.US) and maintained its target price of $318. This indicates the firm's continued confidence in the company's stock performance.

Citizens cuts Spruce Biosciences stock price target on share dilution

Citizens has lowered its price target for Spruce Biosciences (NASDAQ: SPRB) from $150.00 to $144.00, citing potential share dilution indicated in the company's 10-Q filing, while maintaining a Market Outperform rating. Despite the reduction, the new target still suggests significant upside, though InvestingPro data …

Silence Therapeutics Locks In $175 Million to Fuel siRNA Pipeline After Upsized ADS Offering

Silence Therapeutics has secured $175 million in funding through an upsized public offering of American depositary shares (ADSs), exceeding its initial target of $150 million. This capital infusion follows positive Phase 2 results for its siRNA candidate, divesiran, in treating polycythemia vera, where it …

Pharvaris (NASDAQ:PHVS) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Kyntra Bio announced its second quarter 2026 financial results and provided a business update, highlighting significant progress in its oncology and rare disease pipeline. The company is on track for interim analysis of its Phase 2 trial for FG-3246 in mCRPC and aims to …

All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy

Mdxhealth Reports Second Quarter 2026 Financial Results

Mdxhealth reported a 16% increase in second-quarter 2026 revenue, reaching $27.2 million, driven by strong recovery in its tissue-based business and integration of ExoDx. The company reaffirmed its 2026 revenue guidance of $110-115 million and expects to return to positive adjusted EBITDA by the …

Sands Capital group (NASDAQ: IKT) discloses 9.3% Inhibikase stake plus large warrants

Sands Capital Life Sciences Pulse Fund II, L.P., along with related entities, has reported a beneficial ownership of 9.3% in Inhibikase Therapeutics, Inc. This stake includes 13,018,965 shares of common stock and substantial warrants for an additional 15.5 million shares, although these warrants are …

JPMorgan Chase & Co. Issues Pessimistic Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price

Nanobiotix S.A. (NBTX) investor group reports 9.4% stake and pre-funded warrants

An investor group led by Invus Public Equities, L.P. has reported a 9.4% beneficial ownership stake in Nanobiotix S.A. (NBTX), comprising 4,483,275 ordinary shares and 345,099 pre-funded warrants. The warrants are exercisable at Euro 0.03 per share and expire in May 2036. This filing, …